The rising prevalence of cancer significantly drives the global antibody-drug conjugates (ADC) market, increasing demand for targeted, effective treatments. ADCs offer precise cancer cell targeting with reduced harm to healthy tissues by combining monoclonal antibodies with potent cytotoxic drugs. As cancer rates climb, pharmaceutical companies are investing heavily in ADC technology to meet the need for more personalized treatments, especially for challenging cancer types. This growth in the cancer patient population accelerates ADC clinical trials, regulatory approvals, and commercial launches, further advancing the ADC market. The rising prevalence of cancer significantly boosts the global ADC market by increasing the demand for targeted, effective therapies. ADCs, with their ability to deliver potent treatments directly to cancer cells while sparing healthy tissue, have gained attention as a promising solution. This growing cancer burden drives research, development, and investment in ADC technology, pushing forward new advancements and expanding the market.
Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/global-antibody-drug-conjugates-market
Data Bridge Market Research analyzes that the Global Antibody Drug Conjugates (ADC) Market size was valued at USD 9.33 billion in 2023 and is projected to reach USD 29.69 billion by 2031, with a CAGR of 15.6% during the forecast period of 2024 to 2031.
Key Findings of the Study
Advances in Antibody-Drug Conjugate (ADC) Technology
Advances in antibody-drug conjugate (ADC) technology are driving growth in the global ADC market by enhancing both treatment effectiveness and safety in cancer care. Key innovations include improved linkers for stable, precise drug delivery that targets cancer cells while sparing healthy tissue. Next-generation ADCs with optimized payloads and biomarker-driven patient selection ensure that therapies reach those who will benefit most, minimizing side effects. Additionally, improved manufacturing processes are lowering production costs, increasing access, and encouraging greater investment in ADC development, all contributing to a robust pipeline and expanding market interest.
Innovations such as enhanced linker systems and effective drug payloads improve the precision and safety of cancer treatments. Biomarker-guided strategies enhance patient targeting for optimal efficacy. Improved manufacturing techniques have made ADCs more accessible and cost-effective, attracting investment and expanding therapy options. Overall, these advancements boost ADC effectiveness and stimulate market growth and interest from the pharmaceutical industry.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Year
|
2022 (Customizable 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
By Product (Enhertu, Kadcyla, Trodelvy, Polivy, Adcetris, Padcev, Besponsa, Elahere, Zylonta, Mylotarg, Tivdak, and Others), Antigen Component (HER2 Receptor, Trop-2, CD79B, CD30, Nectin 4, CD22, CD19, CD33, Tissue Factors, and Others), Antibody Component (Third Generation ADCs, Second Generation ADCs, Fourth Generation ADCs, and First Generation ADCs), Linkers Component (Cleavable Linkers and Non Cleavable Linkers), Cytotoxic Payloads or Warheads Component (DNA Damaging Agents and Microtubule Disrupting Agents), Linker Technology (Peptide Linkers, Thioether Linkers, Hydrazone Linkers, and Disulfide Linkers), Conjugation Technology (Site-Specific Conjugation and Chemical Conjugation), Indication (Breast Cancer, Blood Cancer (Leukemia, Lymphoma), Lung Cancer, Gynecological Cancer, Gastrointestinal Cancer, Genitourinary Cancer, and Others), End User (Hospitals, Specialty Center, Clinics, Ambulatory Centers, Home Healthcare, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Belgium, Netherlands, Switzerland, Austria, Ireland, Poland, Norway, Hungary, Lithuania, Rest of Europe, Japan, China, India, Australia, Singapore, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, and Rest of Middle East and Africa
|
|
Market Players Covered
|
DAIICHI SANKYO COMPANY, LIMITED (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc. (U.S.), Astellas Pharma Inc. (Japan), Takeda (Japan), Pfizer Inc. (U.S.), Abbvie (U.S.), ADC Therapeutics (Switzerland), Amgen, Inc. (California), AstraZeneca (England), Bayer (Germany), Byondis (Netherlands), EISAI INC (Japan), GSK plc (UK), Johnson & Johnson Services, Inc. (U.S.), Oxford BioTherapeutics (England), Remegen (China), Sanofi (France), and Sutra Biopharma, Inc. (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
Global Antibody-Drug Conjugates (ADC) market is segmented into ten notable segments which are based on product, antigen component, antibody component, linkers component, cytotoxic payloads or warheads component, linker technology, conjugation technology, indication, end user, distribution channel.
- On the basis of product, the market is segmented into enhertu, kadcyla, trodelvy, polivy, adcetris, padcev, besponsa, elahere, zylonta, mylotarg, tivdak, and others
In 2024, the enhertu segment is expected to dominate the market with a market share of 39.22%
In 2024, the enhertu segment is expected to dominate the market with a market share of 39.22% due to its high efficacy and favorable safety profile in treating HER2-positive cancers, alongside its expanded approval for multiple cancer types, which increases its clinical and market adoption.
- On the basis of antigen component, the market is segmented into HER2 Receptor, Trop-2, CD79B CD30, nectin 4, CD22, CD19, CD33, tissue factors, and others
In 2024, the HER2 receptor segment is expected to dominate the market with a market share of 59.62%
In 2024, the HER2 receptor segment is expected to dominate the market with a market share of 59.62% due to the high prevalence of HER2-positive cancers, such as breast and gastric cancers, and the proven effectiveness of HER2-targeted ADCs in providing significant clinical benefits for these conditions.
- On the basis of antibody component, the market is segmented into third generation ADCs, second generation ADCs, fourth generation ADCs, and first generation ADCs. In 2024, the third generation ADCs segment is expected to dominate the market with a market share of 56.17%
- On the basis of linkers component, the market is segmented into cleavable linkers and non cleavable linkers. In 2024, the cleavable linkers segment is expected to dominate the market with a market share of 79.31%
- On the basis of cytotoxic payloads or warheads component, the market is segmented into DNA damaging agents and microtubule disrupting agents. In 2024, the DNA damaging agents segment is expected to dominate the market with a market share of 62.67%
- On the basis of linker technology, the market is segmented into peptide linkers, thioether linkers, hydrazone linkers, and disulfide linkers. in 2024, the peptide linkers segment is expected to dominate the market with a market share of 61.15%
- On the basis of conjugation technology, the market is segmented into Site-Specific Conjugation, and Chemical Conjugation. In 2024, the Site-Specific Conjugation segment is expected to dominate the market with a market share of 56.28%
- On the basis of indication, the market is segmented into Breast Cancer, Blood Cancer (Leukemia, Lymphoma), Lung Cancer, Gynecological Cancer, Gastrointestinal Cancer, Genitourinary Cancer, and Others. In 2024, the Breast Cancer segment is expected to dominate the market with a market share of 42.51%
- On the basis of end user, the market is segmented into hospitals, specialty center, clinics, ambulatory centers, home healthcare, and others. In 2024, the hospitals segment is expected to dominate the market with a market share of 59.81%
- On the basis of distribution channel, the market is segmented into direct tenders, retail sale, and others. In 2024, the direct tenders segment is expected to dominate the market with a market share of 66.23%
Major Players
Data Bridge Market Research analyzes DAIICHI SANKYO COMPANY, LIMITED (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc. (U.S.), Astellas Pharma Inc. (Japan), and Takeda (Japan) as the major market players of the market.
Market Development
- In October 2024, Daiichi Sankyo and AstraZeneca's ENHERTU has received conditional approval in China as the first HER2-directed therapy for adult patients with HER2 mutant metastatic non-small cell lung cancer (NSCLC). This approval, based on positive results from the DESTINY-Lung02 and DESTINY-Lung05 studies, highlights ENHERTU's efficacy in previously treated patients. This marks the fourth indication for ENHERTU in China across various tumor types, enhancing the companies' oncology portfolio and addressing a significant unmet need in lung cancer treatment
- In October 2024, Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) in Japan for ENHERTU (trastuzumab deruxtecan) to treat adult patients with HER2 low or ultralow unresectable or recurrent breast cancer. The submission is based on DESTINY-Breast06 trial results, showing significant improvement in progression-free survival compared to standard chemotherapy. If approved, ENHERTU could become the first HER2-directed therapy and antibody-drug conjugate in this indication in Japan, addressing a critical need in breast cancer treatment and enhancing the company's oncology offerings
- In March 2023, Roche announced its collaboration with Eli Lilly to develop the Elecsys Amyloid Plasma Panel. This innovative blood test aimed to facilitate earlier Alzheimer’s diagnosis, addressing significant barriers and improving access to timely treatments for patients
- In October 2024, Astellas Pharma has received FDA approval for VYLOY (zolbetuximab-clzb) in combination with chemotherapy as a first-line treatment for adults with HER2-negative gastric or gastroesophageal junction adenocarcinoma, specifically targeting CLDN18.2-positive tumors. This makes VYLOY the first CLDN18.2-targeted therapy approved in the U.S. Approximately 38% of screened patients had CLDN18.2-positive tumors, highlighting a significant treatment opportunity. The approval, supported by collaboration with Roche on a companion diagnostic test, represents a major advancement in addressing advanced-stage gastric cancers
Regional Analysis
Geographically, the countries covered in the global antibody-drug conjugates (ADC) market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Belgium, Netherlands, Switzerland, Austria, Ireland, Poland, Norway, Hungary, Lithuania, Rest of Europe, Japan, China, India, Australia, Singapore, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, and Rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is the dominant region in the market during the forecast period of 2024 to 2031
North America is expected to dominate the market due to the region's advanced healthcare infrastructure, high prevalence of cancer, strong regulatory support, and substantial investments in oncology research and development, driving the adoption of innovative ADC therapies.
Asia-Pacific is estimated to be the fastest-growing region in the market during the forecast period of 2024 to 2031
Asia-Pacific is expected to grow during the forecast period ue to rising investments in healthcare infrastructure, increasing prevalence of cancer, and growing demand for targeted therapies across emerging economies.
For more detailed information about the global Antibody-Drug Conjugates (ADC) market report, click here – https://www.databridgemarketresearch.com/fr/reports/global-antibody-drug-conjugates-market
